Actively Recruiting
Evaluating Pridopidine Versus Placebo to Slow Huntingtons Disease Progression in Adults A Randomized, Double-Blind Phase 3 Study With a Two-Year Open-Label Extension
Led by Prilenia · Updated on 2026-11-04
400
Participants Needed
66
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether pridopidine can slow the progression of Huntingtons Disease HD in adults aged 23 to 65. This Phase 3 study compares the effects of pridopidine against a placebo over one year, focusing on overall clinical decline, daily functioning, cognition, motor skills, quality of life, and speech. The study includes participants not currently using antidopaminergic medications and aims to assess safety as well. Participants will first undergo a 1-year randomized, double-blind period where they take either pridopidine or placebo capsules. The treatment begins with a 2-week titration of once-daily dosing, followed by twice-daily dosing for 50 weeks. Following this, all participants who complete the initial year may join a 2-year open-label extension where everyone receives pridopidine, including those originally on placebo. During both periods, participants will attend multiple clinic visits and telephone safety calls. Throughout the study, participants will visit the clinic six times in the first year and six times during the extension, with additional safety phone calls. Researchers will monitor changes in the Unified Huntingtons Disease Rating Scale, functional capacity, motor function, cognition, and quality of life. Safety and tolerability will be closely observed. The total participation period can last up to three years, including both the initial and extension phases.
CONDITIONS
Brief Title
Pridopidine Phase 3 Study in Huntington's Disease
Research Team
P
Prilenia Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here